Your browser doesn't support javascript.
loading
Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.
Moding, Everett J; Liu, Yufei; Nabet, Barzin Y; Chabon, Jacob J; Chaudhuri, Aadel A; Hui, Angela B; Bonilla, Rene F; Ko, Ryan B; Yoo, Christopher H; Gojenola, Linda; Jones, Carol D; He, Jianzhong; Qiao, Yawei; Xu, Ting; Heymach, John V; Tsao, Anne; Liao, Zhongxing; Gomez, Daniel R; Das, Millie; Padda, Sukhmani K; Ramchandran, Kavitha J; Neal, Joel W; Wakelee, Heather A; Loo, Billy W; Lin, Steven H; Alizadeh, Ash A; Diehn, Maximilian.
  • Moding EJ; Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
  • Liu Y; Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
  • Nabet BY; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chabon JJ; Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
  • Chaudhuri AA; Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
  • Hui AB; Department of Radiation Oncology, Washington University, St. Louis, MO, USA.
  • Bonilla RF; Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
  • Ko RB; Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
  • Yoo CH; Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
  • Gojenola L; Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
  • Jones CD; Department of Pathology, Stanford University, Stanford, CA, USA.
  • He J; Department of Pathology, Stanford University, Stanford, CA, USA.
  • Qiao Y; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Xu T; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Heymach JV; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tsao A; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Liao Z; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gomez DR; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Das M; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Padda SK; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ramchandran KJ; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
  • Neal JW; Department of Medicine, VA Palo Alto Health Care System, Palo Alto, CA, USA.
  • Wakelee HA; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
  • Loo BW; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
  • Lin SH; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
  • Alizadeh AA; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
  • Diehn M; Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
Nat Cancer ; 1(2): 176-183, 2020 02.
Article en En | MEDLINE | ID: mdl-34505064
ABSTRACT
Circulating tumor DNA (ctDNA) molecular residual disease (MRD) following curative-intent treatment strongly predicts recurrence in multiple tumor types, but whether further treatment can improve outcomes in patients with MRD remains unclear. We applied CAPP-Seq ctDNA analysis to 218 samples from 65 patients receiving chemoradiation therapy (CRT) for locally advanced NSCLC, including 28 patients receiving consolidation immune checkpoint inhibition (CICI). Patients with undetectable ctDNA after CRT had excellent outcomes whether or not they received CICI. Among such patients, one died from CICI-related pneumonitis, highlighting the potential utility of only treating patients with MRD. In contrast, patients with MRD after CRT who received CICI had significantly better outcomes than patients who did not receive CICI. Furthermore, the ctDNA response pattern early during CICI identified patients responding to consolidation therapy. Our results suggest that CICI improves outcomes for NSCLC patients with MRD and that ctDNA analysis may facilitate personalization of consolidation therapy.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / ADN Tumoral Circulante / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / ADN Tumoral Circulante / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article